Sturgill, E. R., Rolig, A. S., Linch, S. N., Mick, C., Kasiewicz, M. J., Sun, Z., . . . Redmond, W. L. (2021). Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. Oncoimmunology.

Sturgill, Elizabeth R., Annah S. Rolig, Stefanie N. Linch, Courtney Mick, Melissa J. Kasiewicz, Zhaoyu Sun, Peter G. Traber, Harold Shlevin, and William L. Redmond. "Galectin-3 Inhibition With Belapectin Combined With Anti-OX40 Therapy Reprograms the Tumor Microenvironment to Favor Anti-tumor Immunity." Oncoimmunology 2021.

Sturgill, Elizabeth R., et al. "Galectin-3 Inhibition With Belapectin Combined With Anti-OX40 Therapy Reprograms the Tumor Microenvironment to Favor Anti-tumor Immunity." Oncoimmunology 2021.